Lead Sponsor

Orion Corporation, Orion Pharma

Age

35 - No limit years

Sex

ALL

Healthy Volunteers

No

•Subjects with idiopathic Parkinson's disease and early wearing-off symptoms treated with standard levodopa/DDCI treatment
•Age \>35 - years
•Hoehn and Yahr stage 1-3 performed during the 'ON'-stage
•At least 1 symptom identified by WOQ-9
•Dosing frequency of 3-4 doses of standard-release levodopa/DDCI (maximum total daily dose of 600 mg of levodopa)

•Atypical or symptomatic Parkinson's disease
•Unpredictable OFF-periods
•Any peak-dose dyskinesia. 'OFF'-state dystonia is allowed
•Use of any rescue medications to treat symptoms of 'OFF'-state. 1 dose of soluble levodopa/DDCI is allowed.
•Concomitant treatment with non-selective monoamine oxidase (MAO) inhibitor or simultaneous use of higher than recommended doses of MAO-A and MAO-B inhibitors (selegiline 10 mg or rasagiline 1 mg allowed) or use of apomorphine.